Back to Research Home
KMDAKamada
Health Care · Biotechnology: Pharmaceutical Preparations · Small
$7.77+0.52%
As of 23 Oct 2026Mkt cap $485M
Stage 13
WAIT
Fundamentals
40.7/75
Technical
9.2/15
Independent
49.9/90
GCAE viewevidence is stale or freshness is unknown
Price
- 1M
- −12.0%
- 3M
- +11.2%
- 6M
- −6.2%
- 1Y
- +14.3%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- —
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- —
- FCF yield
- —
Quality
- ROIC
- 11.4%
- Operating margin
- 12.5%
- FCF margin
- —
- Current ratio
- 4.1x
Growth
- Revenue growth
- +12.1%Latest FY YoY
- Revenue CAGR
- +14.9%
- EPS CAGR
- +52.8%
- FCF CAGR
- —
Capital
- Share-count trend
- +4.3%3Y annualised
- Net cash
- $64M-2.5x OCF
Annual trend
- CAGR 2021–2025
- +14.9%
- Latest · 2025
- $0B
- YoY
- +12.1%
GCAE Research
- Quality Research
- NOT FLAGGED
- Acceleration Radar
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
evidence is stale or freshness is unknown
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-09
More details & evidence
Production decision
- Stage 13
- WAIT
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- stale
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- NOT FLAGGED
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded